AR102782A1 - Composición farmacéutica, su preparación y sus usos - Google Patents
Composición farmacéutica, su preparación y sus usosInfo
- Publication number
- AR102782A1 AR102782A1 ARP150103850A ARP150103850A AR102782A1 AR 102782 A1 AR102782 A1 AR 102782A1 AR P150103850 A ARP150103850 A AR P150103850A AR P150103850 A ARP150103850 A AR P150103850A AR 102782 A1 AR102782 A1 AR 102782A1
- Authority
- AR
- Argentina
- Prior art keywords
- nanoparticle
- pharmaceutical
- carrier
- biocompatible
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composición farmacéutica que comprende la combinación de (i) al menos una nanopartícula biocompatible y de (ii) al menos un portador que comprende al menos un compuesto farmacéutico, para administrar a un sujeto que necesita de tal compuesto farmacéutico, en donde la combinación de la al menos una nanopartícula biocompatible y del al menos un portador que comprende los compuestos farmacéuticos potencia la eficacia de los compuestos de interés. La dimensión más larga de la nanopartícula biocompatible está típicamente entre aproximadamente 4 y aproximadamente 500 nm y su valor de carga en superficie absoluto es de al menos 10 mV (|10 mV|). El portador carece, además, de cualquier agente estéricamente estabilizante de superficie. Composición para usar para la administración de los compuestos farmacéuticos en un sujeto que lo necesita, en donde la al menos una nanopartícula biocompatible y el al menos un portador que comprende el al menos un compuesto farmacéutico se han de administrar por separado en un sujeto que necesita de dicho compuesto farmacéutico, típicamente entre más de 5 minutos y aproximadamente 72 horas entre sí. Reivindicación 4: La composición farmacéutica de acuerdo con la reivindicación 3, en donde la nanopartícula se selecciona de una nanopartícula a base de lípidos, una nanopartícula a base de proteínas, una nanopartícula a base de polímero, una nanopartícula a base de copolímero, una nanopartícula a base de carbono y una nanopartícula de tipo viral.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14306875 | 2014-11-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR102782A1 true AR102782A1 (es) | 2017-03-22 |
Family
ID=52013982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150103850A AR102782A1 (es) | 2014-11-25 | 2015-11-24 | Composición farmacéutica, su preparación y sus usos |
Country Status (17)
Country | Link |
---|---|
US (1) | US10765632B2 (es) |
EP (1) | EP3236934B1 (es) |
JP (1) | JP6789960B2 (es) |
CN (1) | CN107106703A (es) |
AR (1) | AR102782A1 (es) |
AU (1) | AU2015352685B2 (es) |
BR (1) | BR112017010953B1 (es) |
CA (1) | CA2968919C (es) |
EA (1) | EA201791147A1 (es) |
HK (1) | HK1245085A1 (es) |
IL (2) | IL252462B (es) |
MX (2) | MX2017006812A (es) |
NZ (1) | NZ769187A (es) |
SG (1) | SG11201704219UA (es) |
TW (1) | TW201628656A (es) |
UA (1) | UA123665C2 (es) |
WO (1) | WO2016083333A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112107558A (zh) * | 2013-05-30 | 2020-12-22 | 库拉迪格姆公司 | 药物组合物、制备及其用途 |
HUE056175T2 (hu) | 2014-11-25 | 2022-01-28 | Curadigm Sas | Gyógyászati készítmények, elõállításuk és alkalmazásaik |
WO2016083343A1 (en) * | 2014-11-25 | 2016-06-02 | Nanobiotix | Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof |
JP6722688B2 (ja) | 2014-11-25 | 2020-07-15 | キュラディグム・エスアエスCuradigm Sas | 医薬組成物、調製及びその使用 |
JP2018516256A (ja) | 2015-05-28 | 2018-06-21 | ナノビオティックスNanobiotix | 治療用ワクチンとしての使用のためのナノ粒子 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4280918A (en) | 1980-03-10 | 1981-07-28 | International Business Machines Corporation | Magnetic particle dispersions |
GB9509321D0 (en) | 1995-05-09 | 1995-06-28 | Zylepsis Ltd | Methods of and substances for inhibiting oxidative enzymes |
JPH10120597A (ja) | 1996-10-22 | 1998-05-12 | Eiken Chem Co Ltd | リンパ節高集積性コロイド粒子 |
US20050090732A1 (en) | 2003-10-28 | 2005-04-28 | Triton Biosystems, Inc. | Therapy via targeted delivery of nanoscale particles |
EP1701745B1 (en) * | 2003-12-22 | 2014-12-10 | Bracco Suisse S.A. | Gas-filled microvesicle assembly for contrast imaging |
EP1720521A4 (en) * | 2004-02-10 | 2008-11-05 | Barnes Jewish Hospital | IMPROVED EFFICIENCY AND SAFETY OF TARGETED MEANS WITH DECOY SYSTEMS |
US20060264804A1 (en) * | 2005-04-07 | 2006-11-23 | Yoram Karmon | Device and kit for delivery of encapsulated substances and methods of use thereof |
WO2006127962A2 (en) * | 2005-05-25 | 2006-11-30 | Becton, Dickinson And Comapny | Particulate formulations for intradermal delivery of biologically active agents |
DE102005039579B4 (de) | 2005-08-19 | 2022-06-30 | Magforce Ag | Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen |
WO2007122956A1 (ja) | 2006-03-24 | 2007-11-01 | Toto Ltd. | 酸化チタン複合体粒子、その分散液、およびそれらの製造方法 |
JP2009536151A (ja) | 2006-03-30 | 2009-10-08 | 富士フイルム株式会社 | ナノ粒子 |
WO2007128066A1 (en) | 2006-05-04 | 2007-11-15 | University Of South Australia | Drug release from nanoparticle-coated capsules |
EP2190411A2 (en) * | 2007-08-21 | 2010-06-02 | Alza Corporation | Liposome compositions for in vivo administration of boronic acid compounds |
FR2922106B1 (fr) | 2007-10-16 | 2011-07-01 | Univ Claude Bernard Lyon | Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants. |
EP2231765A2 (en) | 2007-12-21 | 2010-09-29 | University Of Guelph | Polysaccharide nanoparticles |
EP2280601A4 (en) | 2008-02-21 | 2012-08-29 | Sequoia Pharmaceuticals Inc | AMINO ACID HEMMER OF CYTOCHROM P450 |
WO2009142754A1 (en) | 2008-05-22 | 2009-11-26 | Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dendritic conjugates and methods of use |
EP2130553A1 (en) | 2008-06-05 | 2009-12-09 | Nanobiotix | Inorganic nanoparticles of high density to destroy cells in-vivo |
US20130023714A1 (en) | 2008-10-26 | 2013-01-24 | Board Of Regents, The University Of Texas Systems | Medical and Imaging Nanoclusters |
GB0921596D0 (en) | 2009-12-09 | 2010-01-27 | Isis Innovation | Particles for the treatment of cancer in combination with radiotherapy |
US8580312B2 (en) | 2010-02-17 | 2013-11-12 | National University Corporation Kobe University | Radiation therapy agent |
ES2675212T3 (es) | 2010-03-26 | 2018-07-09 | Abraxis Bioscience, Llc | Métodos de tratamiento de carcinoma hepatocelular |
GB201009455D0 (en) | 2010-06-04 | 2010-07-21 | King S College London | Nanoparticles and their uses in molecular imaging |
US9782342B2 (en) | 2010-10-11 | 2017-10-10 | Wichita State University | Composite magnetic nanoparticle drug delivery system |
CN103429227B (zh) | 2011-01-31 | 2017-12-19 | 纳米生物技术公司 | 纳米粒子递送系统、其制备及应用 |
US20140227343A1 (en) * | 2011-01-31 | 2014-08-14 | Centre National De La Recherche Scientifique | Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles |
US10251841B2 (en) | 2011-10-17 | 2019-04-09 | Trustees Of Boston University | Polymeric depots for localization of agent to biological sites |
US20150209397A1 (en) | 2012-09-07 | 2015-07-30 | Carnegie Mellon University | Methods and materials for reducing reticuloendothelial system clearance of particles from a subject |
ITRM20120480A1 (it) * | 2012-10-09 | 2014-04-10 | Uni Degli Studi Camerino | Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione. |
US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
CN112107558A (zh) * | 2013-05-30 | 2020-12-22 | 库拉迪格姆公司 | 药物组合物、制备及其用途 |
EP2886128A1 (en) | 2013-12-20 | 2015-06-24 | Nanobiotix | Pharmaceutical composition comprising nanoparticles, preparation and uses thereof |
JP6722688B2 (ja) | 2014-11-25 | 2020-07-15 | キュラディグム・エスアエスCuradigm Sas | 医薬組成物、調製及びその使用 |
KR20170086638A (ko) | 2014-11-25 | 2017-07-26 | 나노비오?스 | 약학 조성물, 이의 제조 및 용도 |
WO2016083343A1 (en) | 2014-11-25 | 2016-06-02 | Nanobiotix | Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof |
HUE056175T2 (hu) | 2014-11-25 | 2022-01-28 | Curadigm Sas | Gyógyászati készítmények, elõállításuk és alkalmazásaik |
-
2015
- 2015-11-24 MX MX2017006812A patent/MX2017006812A/es unknown
- 2015-11-24 AR ARP150103850A patent/AR102782A1/es unknown
- 2015-11-24 JP JP2017546031A patent/JP6789960B2/ja active Active
- 2015-11-24 CA CA2968919A patent/CA2968919C/en active Active
- 2015-11-24 EA EA201791147A patent/EA201791147A1/ru unknown
- 2015-11-24 US US15/529,106 patent/US10765632B2/en active Active
- 2015-11-24 AU AU2015352685A patent/AU2015352685B2/en active Active
- 2015-11-24 SG SG11201704219UA patent/SG11201704219UA/en unknown
- 2015-11-24 UA UAA201706347A patent/UA123665C2/uk unknown
- 2015-11-24 BR BR112017010953-0A patent/BR112017010953B1/pt active IP Right Grant
- 2015-11-24 EP EP15798435.2A patent/EP3236934B1/en active Active
- 2015-11-24 CN CN201580071112.9A patent/CN107106703A/zh active Pending
- 2015-11-24 TW TW104139006A patent/TW201628656A/zh unknown
- 2015-11-24 NZ NZ769187A patent/NZ769187A/en unknown
- 2015-11-24 WO PCT/EP2015/077425 patent/WO2016083333A1/en active Application Filing
-
2017
- 2017-05-23 IL IL252462A patent/IL252462B/en unknown
- 2017-05-24 MX MX2021010595A patent/MX2021010595A/es unknown
-
2018
- 2018-04-03 HK HK18104437.3A patent/HK1245085A1/zh unknown
-
2022
- 2022-01-25 IL IL290114A patent/IL290114A/en unknown
Also Published As
Publication number | Publication date |
---|---|
HK1245085A1 (zh) | 2018-08-24 |
BR112017010953B1 (pt) | 2024-01-16 |
KR20170093860A (ko) | 2017-08-16 |
BR112017010953A2 (pt) | 2018-02-14 |
JP6789960B2 (ja) | 2020-11-25 |
US10765632B2 (en) | 2020-09-08 |
IL252462B (en) | 2022-03-01 |
IL252462A0 (en) | 2017-07-31 |
UA123665C2 (uk) | 2021-05-12 |
IL290114A (en) | 2022-03-01 |
JP2017538783A (ja) | 2017-12-28 |
NZ769187A (en) | 2023-07-28 |
EA201791147A1 (ru) | 2017-11-30 |
MX2021010595A (es) | 2021-09-23 |
TW201628656A (zh) | 2016-08-16 |
CA2968919C (en) | 2023-07-18 |
CA2968919A1 (en) | 2016-06-02 |
US20170258721A1 (en) | 2017-09-14 |
SG11201704219UA (en) | 2017-06-29 |
NZ732995A (en) | 2021-01-29 |
EP3236934B1 (en) | 2024-05-22 |
AU2015352685A1 (en) | 2017-07-13 |
MX2017006812A (es) | 2018-02-12 |
WO2016083333A1 (en) | 2016-06-02 |
CN107106703A (zh) | 2017-08-29 |
EP3236934A1 (en) | 2017-11-01 |
AU2015352685B2 (en) | 2020-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
AR102782A1 (es) | Composición farmacéutica, su preparación y sus usos | |
CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
DOP2018000297A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
UY36766A (es) | Derivados de sulfamoilarilamida ciclados como inhibidores del vhb, procesos de preparación y composiciones farmacéuticas que los contienen | |
CL2016001547A1 (es) | Composiciones para el cuidado oral | |
CL2016001509A1 (es) | Formas cristalinas de los análogos de sofosbuvir antivirales | |
CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
UY36665A (es) | Derivados de ciclohexano sustituidos con amidas | |
AR079890A1 (es) | Estabilizacion de peliculas de oxido de zinc en composiciones bucales | |
AR102779A1 (es) | Composición farmacéutica, su preparación y sus usos | |
GT201400043A (es) | Imidazopiridazinas sustituidas con amino | |
GT201600091A (es) | Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos | |
CU20150071A7 (es) | Composición de liberación demorada que comprende biguanida | |
CL2017001483A1 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
NI201500096A (es) | Compuesto químicos | |
CL2016000008A1 (es) | Tratamiento de lesiones inflamatorias de rosacea con ivermectina. | |
AR102780A1 (es) | Composiciones farmacéuticas, su preparación y sus usos | |
CL2016000026A1 (es) | Nuevos derivados de azabencimidazol | |
AR103350A1 (es) | Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas | |
SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
CL2016002560A1 (es) | Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación. | |
DOP2016000007A (es) | Pirazolpiridinas sustituidas | |
DOP2015000298A (es) | Compuestos nuevos para el tratamiento del cáncer | |
DOP2017000018A (es) | [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |